Rise in incidence of cardiovascular diseases and insomnia are the factors responsible for the augmentation of nocturia market. Various conditions affecting the bladder/prostate can result in having to wake up to urinate. Not treating these conditions may result in continuation to pee beyond the regular intervals, thereby getting categorized as nocturia.
The companies operating in the nocturia market are devising various therapeutic measures to reduce the count of nocturia patients.
They are collaborating with the research institutes to come up with the advanced versions of existing drugs, so that majority of patients can get benefited. This could also avoid the other complications related to improper sleep apart from nocturia.
Nocturia means waking up more than once at night to urinate. Causes include sleep disorders and obstruction to bladder. The treatment includes restricting medications and fluids that cut down the symptoms of overactive bladder.
Nocturia is also called nocturnal urinary frequency. It is observed to a larger extent in people aged 60 and above.
Research states that nocturia is more common in men and individuals assigned male at birth (AMAB) after 50. It further mentions that it is more common amongst the women and individuals assigned female at birth (AFAB) before 50.
Symptoms of nocturia include waking up twice or more in order to pee at night, peeing more on presence of polyuria, and sleepiness and fatigue during the daytime.
The symptoms mentioned above need to be addressed immediately to avoid any further complications. Surgery pertaining to the urinary tract should be conducted with utmost care looking at the sensitivity involved in it.
Increase in sleeplessness worldwide is expected to expand the nocturia market size during the forecast period.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Individuals suffering from congestive heart failure have a reduced flow of renal plasma with increased fraction of filtration at the time of ambulation. This is linked with sodium retention. In such patients, nighttime recumbence enhances sodium excretion and renal hemodynamics, thereby resulting in nocturia.
A weak heart is unable to pump blood efficiently, thereby resulting in fluids getting built up in the body. The kidneys work in order to relieve the body of excessive fluid, thereby resulting in huge quantity of urine production and ultimately frequent urination.
As per the National Institutes of Health, heart failure is a global pandemic affecting more than 26 million people across the globe.
Need to address nocturia caused due to heart failure is thus expanding the nocturia market size.
Obstructive sleep apnea (OSA) results in periodic pauses in breathing at night. OSA is known for repeatedly reducing oxygen levels and airflow during sleep and also influence hormones such that more quantity of urine gets produced.
Additionally, individuals suffering from OSA have sleep interruptions on frequent basis. Therefore, they are more likely of noticing the need to urinate. Research states that nocturia affects 50% of individuals suffering from OSA.
It further states that sleep problems that include insomnia are amongst the root causes of an individual struggling to get back to sleep after visiting the bathroom.
As per the National Institutes of Health, insomnia is prevalent in 10-30% of the global population. Need to combat nocturia in such patients is thus accelerating the nocturia market development.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest nocturia market scenario, North America dominated the nocturia treatment landscape in 2023 and the status quo is expected to remain unchanged during the forecast period.
This is attributed to increase in geriatric population in the U.S. followed by encouragement from the government agencies for R&D activities regarding nocturia treatment.
Europe’s significant nocturia market growth is ascribed to Germany, the U.K., and Italy being at the forefront regarding research pertaining to excessive urination at night.
The key participants in the nocturia market are conducting trials to provide a higher level of relief to patients suffering from frequent urination at night.
AbbVie Inc., Vantia Therapeutics, Astellas Pharma Inc., Urigen Pharmaceuticals Inc., Sumitomo Pharma Co., Ltd., Ferring Pharmaceuticals, Glenmark Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Avadel Pharmaceuticals plc are some of the key players covered in the nocturia market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 3.7 Bn |
| Market Forecast (Value) in 2034 | US$ 8.5 Bn |
| Growth Rate (CAGR) | 8.0% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 3.7 Bn in 2023
It is projected to grow at a CAGR of 8.0% from 2024 to 2034
Growing prevalence of cardiovascular diseases and insomnia
Hospital pharmacies segment accounted for the largest share in 2023
North America was the dominant region in 2023
AbbVie Inc., Vantia Therapeutics, Astellas Pharma Inc., Urigen Pharmaceuticals Inc., Sumitomo Pharma Co., Ltd., Ferring Pharmaceuticals, Glenmark Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Avadel Pharmaceuticals plc
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Nocturia Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Nocturia Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Nocturia Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Type, 2020-2034
6.3.1. Anticholinergic Drugs
6.3.2. Desmopressin
6.3.3. Antibiotics
6.3.4. Antispasmodic
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Nocturia Market Analysis and Forecast, by Indication Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication Type, 2020-2034
7.3.1. Mixed Nocturia
7.3.2. Low Nocturnal Bladder Capacity
7.3.3. Nocturnal Polyuria
7.4. Market Attractiveness Analysis, by Indication Type
8. Global Nocturia Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2020-2034
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Nocturia Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Nocturia Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Type, 2020-2034
10.3.1. Anticholinergic Drugs
10.3.2. Desmopressin
10.3.3. Antibiotics
10.3.4. Antispasmodic
10.3.5. Others
10.4. Market Value Forecast, by Indication Type, 2020-2034
10.4.1. Mixed Nocturia
10.4.2. Low Nocturnal Bladder Capacity
10.4.3. Nocturnal Polyuria
10.5. Market Value Forecast, by Distribution Channel, 2020-2034
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Type
10.7.2. By Indication Type
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Nocturia Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Type, 2020-2034
11.3.1. Anticholinergic Drugs
11.3.2. Desmopressin
11.3.3. Antibiotics
11.3.4. Antispasmodic
11.3.5. Others
11.4. Market Value Forecast, by Indication Type, 2020-2034
11.4.1. Mixed Nocturia
11.4.2. Low Nocturnal Bladder Capacity
11.4.3. Nocturnal Polyuria
11.5. Market Value Forecast, by Distribution Channel, 2020-2034
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Type
11.7.2. By Indication Type
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Nocturia Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Type, 2020-2034
12.3.1. Anticholinergic Drugs
12.3.2. Desmopressin
12.3.3. Antibiotics
12.3.4. Antispasmodic
12.3.5. Others
12.4. Market Value Forecast, by Indication Type, 2020-2034
12.4.1. Mixed Nocturia
12.4.2. Low Nocturnal Bladder Capacity
12.4.3. Nocturnal Polyuria
12.5. Market Value Forecast, by Distribution Channel, 2020-2034
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Type
12.7.2. By Indication Type
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Nocturia Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Type, 2020-2034
13.3.1. Anticholinergic Drugs
13.3.2. Desmopressin
13.3.3. Antibiotics
13.3.4. Antispasmodic
13.3.5. Others
13.4. Market Value Forecast, by Indication Type, 2020-2034
13.4.1. Mixed Nocturia
13.4.2. Low Nocturnal Bladder Capacity
13.4.3. Nocturnal Polyuria
13.5. Market Value Forecast, by Distribution Channel, 2020-2034
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Type
13.7.2. By Indication Type
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Nocturia Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Type, 2020-2034
14.3.1. Anticholinergic Drugs
14.3.2. Desmopressin
14.3.3. Antibiotics
14.3.4. Antispasmodic
14.3.5. Others
14.4. Market Value Forecast, by Indication Type, 2020-2034
14.4.1. Mixed Nocturia
14.4.2. Low Nocturnal Bladder Capacity
14.4.3. Nocturnal Polyuria
14.5. Market Value Forecast, by Distribution Channel, 2020-2034
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Type
14.7.2. By Indication Type
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. AbbVie Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Vantia Therapeutics
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Astellas Pharma Inc.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Urigen Pharmaceuticals Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Sumitomo Pharma Co., Ltd.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Ferring Pharmaceuticals
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Glenmark Pharmaceuticals
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Teva Pharmaceutical Industries Ltd.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Avadel Pharmaceuticals plc
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
List of Tables
Table 01: Global Nocturia Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
Table 02: Global Nocturia Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
Table 03: Global Nocturia Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 04: Global Nocturia Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 05: North America Nocturia Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 06: North America Nocturia Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
Table 07: North America Nocturia Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
Table 08: North America Nocturia Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 09: Europe Nocturia Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 10: Europe Nocturia Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
Table 11: Europe Nocturia Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
Table 12: Europe Nocturia Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 13: Asia Pacific Nocturia Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Asia Pacific Nocturia Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
Table 15: Asia Pacific Nocturia Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
Table 16: Asia Pacific Nocturia Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 17: Latin America Nocturia Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 18: Latin America Nocturia Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
Table 19: Latin America Nocturia Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
Table 20: Latin America Nocturia Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 21: Middle East & Africa Nocturia Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Middle East & Africa Nocturia Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
Table 23: Middle East & Africa Nocturia Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
Table 24: Middle East & Africa Nocturia Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
List of Figures
Figure 01: Global Nocturia Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Nocturia Market Revenue (US$ Bn), by Drug Type, 2023
Figure 03: Global Nocturia Market Value Share, by Drug Type, 2023
Figure 04: Global Nocturia Market Revenue (US$ Bn), by Indication Type, 2023
Figure 05: Global Nocturia Market Value Share, by Indication Type, 2023
Figure 06: Global Nocturia Market Revenue (US$ Bn), by Distribution Channel, 2023
Figure 07: Global Nocturia Market Value Share, by Distribution Channel, 2023
Figure 08: Global Nocturia Market Value Share, by Region, 2023
Figure 09: Global Nocturia Market Value (US$ Bn) Forecast, 2020-2034
Figure 10: Global Nocturia Market Value Share Analysis, by Drug Type, 2023 and 2034
Figure 11: Global Nocturia Market Attractiveness Analysis, by Region, 2024-2034
Figure 12: Global Nocturia Market Value Share Analysis, by Indication Type, 2023 and 2034
Figure 13: Global Nocturia Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 14: Nocturia Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 15: Global Nocturia Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 16: Global Nocturia Market Value Share Analysis, by Region, 2023 and 2034
Figure 17: Global Nocturia Market Attractiveness Analysis, by Region, 2024-2034
Figure 18: North America Nocturia Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 19: North America Nocturia Market Attractiveness Analysis, by Country, 2024-2034
Figure 20: North America Nocturia Market Value Share Analysis, by Country, 2023 and 2034
Figure 21: North America Nocturia Market Value Share Analysis, by Drug Type, 2023 and 2034
Figure 22: North America Nocturia Market Value Share Analysis, by Indication Type, 2023 and 2034
Figure 23: North America Nocturia Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 24: North America Nocturia Market Attractiveness Analysis, by Region, 2024-2034
Figure 25: North America Nocturia Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 26:North America Nocturia Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 27: Europe Nocturia Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 28: Europe Nocturia Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 29: Europe Nocturia Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 30: Europe Nocturia Market Value Share Analysis, by Drug Type, 2023 and 2034
Figure 31: Europe Nocturia Market Value Share Analysis, by Indication Type, 2023 and 2034
Figure 32: Europe Nocturia Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 33: Europe Nocturia Market Attractiveness Analysis, by Region, 2024-2034
Figure 34: Europe Nocturia Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 35: Europe Nocturia Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 36: Asia Pacific Nocturia Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 37: Asia Pacific Nocturia Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 38: Asia Pacific Nocturia Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 39: Asia Pacific Nocturia Market Value Share Analysis, by Drug Type, 2023 and 2034
Figure 40: Asia Pacific Nocturia Market Value Share Analysis, by Indication Type, 2023 and 2034
Figure 41: Asia Pacific Nocturia Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 42: Asia Pacific Nocturia Market Attractiveness Analysis, by Region, 2024-2034
Figure 43: Asia Pacific Nocturia Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 44: Asia Pacific Nocturia Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 45: Latin America Nocturia Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 46: Latin America Nocturia Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 47: Latin America Nocturia Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 48: Latin America Nocturia Market Value Share Analysis, by Drug Type, 2023 and 2034
Figure 49: Latin America Nocturia Market Value Share Analysis, by Indication Type, 2023 and 2034
Figure 50: Latin America Nocturia Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 51: Latin America Nocturia Market Attractiveness Analysis, by Region, 2024-2034
Figure 52: Latin America Nocturia Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 53: Latin America Nocturia Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 54: Middle East & Africa Nocturia Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 55: Middle East & Africa Nocturia Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 56: Middle East & Africa Nocturia Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 57: Middle East & Africa Nocturia Market Value Share Analysis, by Drug Type, 2023 and 2034
Figure 58: Middle East & Africa Nocturia Market Value Share Analysis, by Indication Type, 2023 and 2034
Figure 59: Middle East & Africa Nocturia Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 60: Middle East & Africa Nocturia Market Attractiveness Analysis, by Region, 2024-2034
Figure 61: Middle East & Africa Nocturia Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 62: Middle East & Africa Nocturia Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Nocturia Market
